{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-028535","form_type":"8-K","ticker":"AVTX","cik":"0001534120","company_name":"Avalo Therapeutics, Inc.","filed_at":"2022-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.055706+00:00","generated_at":"2026-06-22T05:22:53.007682+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Avalo Q3 net income $3.2M on $14.5M license; cash $16.9M; AVTX-002 data H1 2023","bullets":["Q3 net income of $3.2M vs $17.4M loss in 2021; net revenues $15M including $14.5M license revenue.","Cash $16.9M at Sep 30 2022, down $37.7M from Dec 31 2021; operating expenses fell $23.6M YTD.","Agreement to sell net economic rights to legacy out-licensed assets (AVTX-007, -501, -611) for $5M due Nov 2022.","Phase 2 PEAK trial of AVTX-002 in non-eosinophilic asthma enrollment to complete by end of 2022; topline data H1 2023.","Pivotal LADDER trial of AVTX-803 in LAD II on track for data in H1 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-028535","json":"https://secwatch.observer/filing/0001628280-22-028535.json","markdown":"https://secwatch.observer/filing/0001628280-22-028535.md","text":"https://secwatch.observer/filing/0001628280-22-028535.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534120/000162828022028535/0001628280-22-028535-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534120/000162828022028535/avtx-20221107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T05:22:53.007682+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cf54d31f637e5f60b6139ef5f0d26b0976b0d033","claim":"Avalo Therapeutics, Inc. reported financial results for the quarter ended September 30, 2022.","evidence_excerpt":"Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced business updates and financial results for the third quarter of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534120/000162828022028535/0001628280-22-028535-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}